The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
X. Huang
No relevant relationships to disclose
Y. M. Ning
No relevant relationships to disclose
M. Mulquin
No relevant relationships to disclose
R. A. Madan
No relevant relationships to disclose
J. L. Gulley
No relevant relationships to disclose
P. G. Kluetz
No relevant relationships to disclose
D. Adelberg
No relevant relationships to disclose
P. M. Arlen
No relevant relationships to disclose
H. L. Parnes
No relevant relationships to disclose
B. Adesunloye
No relevant relationships to disclose
S. M. Steinberg
No relevant relationships to disclose
J. J. Wright
No relevant relationships to disclose
J. B. Trepel
No relevant relationships to disclose
C. Chen
No relevant relationships to disclose
C. Bassim
No relevant relationships to disclose
A. B. Apolo
No relevant relationships to disclose
W. D. Figg
No relevant relationships to disclose
W. L. Dahut
No relevant relationships to disclose